NCT07294469Not yet recruitingPhase 2
Menthol for Improving Movement and Sleep in Parkinson's Disease Patients
Effect of Menthol on Motor Deficits and Sleep Disturbances in Patients With Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 8 Jan 2026
Brief summary (registry, in English)
Parkinson's disease (PD) is a progressive neurological disorder characterized by both motor and non-motor symptoms due to the degeneration of dopamine-producing neurons. There is currently no cure. Menthol, a natural compound that activates TRPM8 receptors, has shown neuroprotective and motor function benefits in preclinical PD models. In mice, distal limb immersion in menthol improved dopamine neuron survival and motor performance. Similar menthol-based interventions improved outcomes in a stroke model and a clinical trial with stroke patients. This study investigates whether topical menthol can offer therapeutic benefits for individuals with PD.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 8 Dec 2025
- Start date
- Dec 2025
- Primary completion date
- Jul 2027
- Lead sponsor
- Taipei Medical University Hospital
- Diseases
- Parkinson disease
- NCT number
- NCT07294469
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 80
- From Dec 2025 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- menthol allergy;
- patients with conditions such as uremia, cirrhosis, congestive heart failure with pulmonary edema, coagulation disorders, epilepsy, alcoholism, drug abuse, or
Other
- pregnant and breastfeeding women;
- diagnosed with secondary and atypical PD;
- deemed unsuitable for participation in this study by the principal investigator.
Who the study is looking for
- aged between 30 and 80 years (inclusive);
- diagnosed with idiopathic PD based on the Brain Bank criteria of the UK Parkinson's Disease Society less than 3 years;
- Hoehn and Yahr stages 1-3 and currently receiving treatment; experiencing sleep disorders with a Pittsburgh Sleep Quality Index (PSQI) \> 5;
- has signed the informed consent form approved by the Institutional Review Board and dated accordingly;
- no changes in PD medications within four weeks prior to participating in this trial, and no dosage changes during the study period;
- able to use other medications that may affect sleep, except those explicitly prohibited, provided the dosage has been stable for the four weeks before screening and remains unchanged during the study.
Age in the registry: 30 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Taipei Medical University Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.